Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PSAP
REST API REST API
Homo sapiens
PSAP is differentially expressed in 311 experiments: 106 organism parts: bone marrow, cerebellum, ... (104 more);, 209 disease states: normal, acute myeloid leukemia, ... (207 more);, 119 cell types 398 cell lines 47 compound treatments and 78 other conditions.
Synonyms SAP1, GLBA
Orthologs psap (Danio rerio)   PSAP (Bos taurus)   PSAP (Gallus gallus)   ENSCING00000006331 (Ciona intestinalis)   Sap-r (Drosophila melanogaster)   psap (Xenopus laevis)   PSAP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term lipid transport, positive regulation of catalytic activity, extracellular space, lysosome, Golgi apparatus, lipid binding, extracellular region, blood coagulation, intracellular membrane-bounded organelle, regulation of MAPKKK cascade, lipid metabolic process, sphingolipid metabolic process, enzyme activator activity, integral to membrane, mitochondrion, platelet degranulation, prostate gland growth, glycosphingolipid metabolic process, epithelial cell differentiation involved in prostate gland development, lysosomal lumen, platelet activation
InterPro Term SapA, SaposinB, Saposin, SapB_1, SapB_2, Saposin_chordata
UniProt Accession P07602, Q53Y86, Q5BJH1, C9JIZ6, B1AVU8, F5H0X6, F8W6Z6
Gene-Disease Assocation GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY, METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY, COMBINED SAPOSIN DEFICIENCY, KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY
Search EB-eye ENSG00000197746
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
Daudi
2
E-MTAB-37, E-GEOD-96
HCC2157
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
Raji
2
E-MTAB-37, E-GEOD-96
392 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
1
2
E-TABM-130, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
not specified
2
E-GEOD-18811, E-GEOD-11755
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
CD14+ monocyte
1
2
E-AFMX-5, E-MEXP-1600, E-TABM-145
skin substitute
1
E-GEOD-3204
113 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (59 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
multiple myeloma
2
E-GEOD-6691, E-MTAB-62
lung adenocarcinoma
1
2
E-MTAB-37, E-MEXP-231, E-MTAB-62
breast carcinoma
1
2
E-TABM-276, E-MEXP-882, E-MTAB-37
glioblastoma
1
2
E-GEOD-6014, E-MTAB-62, E-MTAB-37
trauma
1
E-MTAB-62
203 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (28 experiments)

Factor Value U/D Experiments
none
4
6
E-MEXP-1601, E-TABM-782, E-GEOD-5824, E-MEXP-1958, E-GEOD-412, ... (10 experiments)
control
2
E-GEOD-3284, E-GEOD-3356
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
glucose
1
E-MEXP-941
mercury dichloride
1
E-GEOD-6907
control - keratinocyte growth factor
1
E-GEOD-7216
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-MEXP-1828, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-GEOD-10315, E-GEOD-837, E-GEOD-1692, E-MEXP-1273, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-TABM-26, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-6434, E-GEOD-1657, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-19330, E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-1643, E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922, E-TABM-147

Tumor size
studied in E-GEOD-6532

Processing time: 0.53 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM